Morgan Stanley Rates Mirum Pharmaceuticals (MIRM) buy

Morgan Stanley reiterates its buy rating on Mirum Pharmaceuticals with a price target of $150 as of June 11, 2026, a 50.72% upside from the current price.

By EarningsIQ Research Desk · Published Jun 12, 2026, 9:14 PM EDT · Updated Jun 13, 2026, 1:00 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Morgan Stanley rated Mirum Pharmaceuticals, Inc. ($MIRM) "buy" with a $150 price target on June 11, 2026.

Since the rating, $MIRM is up 7.6% after 1 week, up 19.6% after 1 month and down 19.5% to date (from the $99.54 close on Jun 11, 2026).

MIRM Mirum Pharmaceuticals, Inc.

$80.14 +2.65% year to date

Daily close · Oct 16, 2026

Key Points

Morgan Stanley has reiterated its buy rating on Mirum Pharmaceuticals, setting a target price of $150 following the stock's close at $99.52.
Morgan Stanley's $150 price target implies 50.72% upside from Mirum Pharmaceuticals, Inc.'s ($MIRM) current $99.52 share price.
Mirum Pharmaceuticals reported revenue of $618.1 million, with a growth rate of 37.9% over the past year, highlighting its expanding market presence.
Analysts have a consensus strong buy rating on the stock, with a mean target price of $138.21 based on 14 opinions.

Get $MIRM trade alerts by text

We text you when insiders, Congress or big funds trade $MIRM. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Mirum Pharmaceuticals, Inc. alert may contain errors. Disclosures

Morgan Stanley's Latest Call on Mirum Pharmaceuticals

On June 11, 2026, Morgan Stanley reiterated its buy rating on Mirum Pharmaceuticals, Inc. (MIRM) with a price target of $150. The stock was trading at $99.52 on that day. This reiteration comes as Mirum continues to grow in the biopharmaceutical industry, focusing on treatments for rare diseases.

What This Means for Mirum's Position

Morgan Stanley's reaffirmation does not indicate a change in the number of shares held, but it emphasizes the firm's belief in the company's potential. Mirum remains a compelling player in the biotech sector, especially as it seeks to address challenging medical needs.

Institutional Insights on MIRM

No other institutional actions were reported alongside Morgan Stanley's recent rating, but Mirum's health in the market can be seen through its revenue and growth metrics. As the company continues to build its portfolio of drugs, analysts are keen to see how it performs relative to its peers.

Stock Performance Context

The stock's pricing reflects a notable gap from its 52-week high of $130. This divergence could signal an opportunity for investors looking at future growth potential, especially with a strong buy consensus among analysts.

12-month forecast

$MIRM price target

Mirum Pharmaceuticals, Inc. daily closes and this analyst's $150 target. Not advice.

Recent Earnings

Mirum Pharmaceuticals reported total revenue of $618.1 million, which reflects a robust growth of 37.9%. Their net margin remains negative at -1.39%, indicating ongoing challenges in profitability. The next earnings report is scheduled for November 4, 2026, where more financial insights will be available.

What MIRM Does

Mirum Pharmaceuticals, Inc., headquartered in Foster City, California, specializes in developing therapies for rare and orphan diseases. Its lead product, LIVMARLI, addresses cholestatic pruritus in patients with Alagille syndrome, showcasing the company’s commitment to innovative treatments.

What’s Next for Mirum Pharmaceuticals

Looking ahead, investors will be eager for the upcoming earnings report on November 4, 2026, which will provide further insights into the company’s performance. As a reminder, Morgan Stanley's rating reflects their view as of June 11 and may not indicate current positions.